Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for SCYNEXIS, Inc. (SCYX : NSDQ)

• Company Description    SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $1.18 Daily Weekly Monthly 20 Day Moving Average: 165,578 shares Shares Outstanding: 41.92 (millions) Market Capitalization: $49.47 (millions) Beta: 1.75 52 Week High: $1.66 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 47.21% 44.55% 12 Week 58.50% 43.90% Year To Date -2.48% -12.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 EVERTRUST PLAZA 13TH FLOOR - JERSEY CITY,NJ 07302 USA ph: 201-884-5485 fax: 201-884-5490 ikoffler@lifesciadvisors.com http://www.scynexis.com

• General Corporate Information    Officers David Angulo - Chief Executive Officer Ivor Macleod - Chief Financial Officer Guy Macdonald - Director David Hastings - Director Steven C. Gilman - Director Peer Information SCYNEXIS, Inc. (GSAC) SCYNEXIS, Inc. (CASI) SCYNEXIS, Inc. (ALCD.) SCYNEXIS, Inc. (OMNN) SCYNEXIS, Inc. (CGPI.) SCYNEXIS, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 811292200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 41.92 Most Recent Split Date: 7.00 (0.10:1) Beta: 1.75 Market Capitalization: $49.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.04 Price/Cash Flow: - Price / Sales: 15.18 EPS Growth vs. Year Ago Period: 53.33% vs. Previous Quarter: 17.65% Sales Growth vs. Year Ago Period: 85.33% vs. Previous Quarter: 430.74% ROE 06/30/25 - -43.04 03/31/25 - -53.47 12/31/24 - -46.56 ROA 06/30/25 - -28.21 03/31/25 - -32.86 12/31/24 - -27.78 Current Ratio 06/30/25 - 5.20 03/31/25 - 5.83 12/31/24 - 3.00 Quick Ratio 06/30/25 - 5.20 03/31/25 - 5.83 12/31/24 - 3.00 Operating Margin 06/30/25 - -688.92 03/31/25 - -1,141.37 12/31/24 - -770.90 Net Margin 06/30/25 - -599.05 03/31/25 - -1,030.04 12/31/24 - -568.29 Pre-Tax Margin 06/30/25 - -610.71 03/31/25 - -1,044.49 12/31/24 - -564.26 Book Value 06/30/25 - 1.14 03/31/25 - 1.30 12/31/24 - 1.45 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©